Nonalcoholic steatohepatitis (NASH) is usually diagnosed in 40-60 year old patients with metabolic syndrome, but many common mouse models involve dietary or chemical interventions that begin at young ages. We established 3 NASH models using year-old C57BL/6J (B6J) males with approximate human age equivalence of 40 years. In one model, aged mice ate Gubra Amylin NASH (GAN) diet (40 kcal% fat with 18 kcal% palm oil; 20% fructose; 2% cholesterol; N=12) or chow diet (6% fat by weight; N=10) for 5 months. Aged mice fed GAN had rapid signs of liver damage: by 1 month, serum alanine aminotransferase (ALT) rose from 53 ± 20 to 309 ± 188 IU/L (Repeated measures ANOVA; P < 0.0001) and aspartate aminotransferase (AST) increased from 77 ± 33 to 399 ± 420 IU/L (P < 0.0001); values were stable in aged B6J fed chow. In contrast, liver damage progressed more slowly when B6J were started on GAN as young adults (6 weeks old; N=11); ALT increased from 27 ± 5 to 231 ± 96 IU/L and AST from 53 ± 18 to 177 ± 88 IU/L after 5 months. After 1 month, GAN-fed aged B6J serum cholesterol rose from 166 ± 24 to 290 ± 65 mg/dL (P < 0.0001) but not in aged B6J fed chow or young B6J fed GAN. Triglycerides and glucose did not change after 5 months in any group, while ALT, AST and cholesterol remained high in aged GAN mice throughout. Histopathology of aged B6J fed GAN for 5 months showed severe submassive to diffuse steatosis; perivascular, bridging, and perisinusoidal fibrosis; necrosis and hepatocyte degeneration. A second model was created by treating year-old B6J mice with 3 daily doses of 50 mg/kg streptozotocin (STZ) and 60 kcal% high fat diet (STZ-HFD). Serum glucose, ALT, AST and cholesterol rose in STZ-HFD mice. Steatosis and fibrosis were less severe in STZ-HFD mice compared to aged mice fed GAN. In a third model, young and aged B6J responded similarly to a choline-deficient, reduced-methionine diet with elevated ALT and AST; reduced glucose, cholesterol and body weight; and comparable histopathology scores. The results show the value of studying mice at a life stage that more closely resembles age of clinical diagnosis.

Disclosure

J. Serrano: None. R.D. French: None. K. Leighton: None. A. SanMiguel: None. M. Ellis: None. D. Imai: None. A. Schile: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.